ArticleFrontiers in genetics2026
Combined single-cell transcriptome and Mendelian randomization to identify and validate prognostic genes associated with endoplasmic reticulum stress and butyrate metabolism in lung adenocarcinoma.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is a prevalent and aggressive subtype of lung cancer, with a 5-year survival rate below 20% due to late-stage diagnosis and drug resistance. Endoplasmic reticulum stress (ERS) and butyrate metabolism (BM) play critical roles in tumor progression, but their co-regulatory features in LUAD remain unclear. Methods: This study integrated single-cell transcriptome analysis and Mendelian randomization (MR) to identify prognostic genes associated with ERS and BM in LUAD. Public datasets were analyzed using weighted gene co-expression network analysis, differential expression analysis, and MR. A risk model and nomogram were constructed, and immune microenvironment, gene set enrichment, and single-cell analyses were performed to validate findings. Moreover, the expression of prognostic genes was validated in different Non-small cell lung cancer (NSCLC) cell lines through reverse transcription quantitative polymerase chain reaction (RT-qPCR). Results: Seven prognostic genes ( Conclusion: This study identifies seven ERS- and BM-related prognostic genes and highlights macrophages as pivotal in LUAD progression, the expression differences of candidate genes were verified by RT-qPCR assay. These findings provide novel insights into LUAD diagnosis, prognosis, and potential therapeutic targets, offering a foundation for precision medicine strategies. Further validation in clinical cohorts and functional studies is warranted to translate these discoveries into clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.